Bow Chung, MD
Advanced Heart Failure and Transplant Cardiology · Chicago, ILNPI 1073809570
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $76,080 of the $86,075 with a category attached, or 88.4%. 28 manufacturers reported payments, led by Boehringer Ingelheim at 36.2% of the total. 2025 is the largest year on record at $30,796, more than ten times the $1,631 reported in 2019.
Across 230 payments — averaging $374.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$31K
- Pfizer$24K
- Bridgebio Pharma, Inc.$20K
- Abbott$5K
- Lilly USA, LLC$3K
- AstraZeneca$338
- plus $2K from 22 others
What the payments were for
- Consulting fees$1,8742%
- Speaking & faculty fees$76,08088%
- Travel & lodging$1,1321%
- Food & beverage$6,9808%
- Education$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 28 | $31,133 |
| Pfizer | 31 | $24,108 |
| Bridgebio Pharma, Inc. | 14 | $20,479 |
| Abbott | 73 | $5,053 |
| Lilly USA, LLC | 5 | $2,990 |
| AstraZeneca | 19 | $338 |
| Novartis | 13 | $241 |
| Cvrx, Inc. | 3 | $208 |
| Medtronic(2 entities) | 2 | $179 |
| Boston Scientific | 2 | $171 |
| E.r. Squibb & Sons, L.L.C. | 8 | $144 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $143 |
| Abiomed | 1 | $139 |
| Paragonix Technologies, Inc. | 2 | $138 |
| Actelion Pharmaceuticals US, Inc. | 1 | $119 |
| Amgen | 4 | $85 |
| Edwards Lifesciences | 2 | $55 |
| Lantheus Medical Imaging, Inc. | 3 | $50 |
| Portola Pharmaceuticals, LLC | 2 | $46 |
| United Therapeutics Corporation | 2 | $40 |
| Johnson & Johnson | 2 | $39 |
| Lexicon Pharmaceuticals, Inc. | 2 | $37 |
| Merck | 1 | $32 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Sanofi | 1 | $25 |
| Akcea Therapeutics, Inc. | 1 | $21 |
| Medicomp Inc | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$33,687
- VYNDAQEL$23,550
- Attruby$20,437
- CARDIOMEMS$1,874
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$860
- HeartMate 3 Left Ventricular Dev$503
- CardioMEMS HF System$272
- Barostim Neo System$171
- Claria MRI$151
- Impella$139
- Watchman$121
- OPSUMIT$119
- HeartMate 3 Left Ventricular Assist Device$100
How this compares
$86,075 in reported general payments places this provider in the 85th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.
See all advanced heart failure and transplant cardiology providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 35 | $1,248,146 |
| EntrestoSacubitril/Valsartan | 92 | $147,331 |
| FarxigaDapagliflozin Propanediol | 60 | $81,463 |
| JardianceEmpagliflozin | 59 | $56,306 |
| EliquisApixaban | 39 | $33,028 |
| OzempicSemaglutide | 19 | $30,193 |
| Repatha SureclickEvolocumab | 11 | $9,325 |
| Metoprolol Succinate | 115 | $1,973 |
| Disopyramide Phosphate | 12 | $1,787 |
| Carvedilol | 106 | $1,402 |
| Torsemide | 40 | $1,328 |
| Eplerenone | 27 | $1,284 |
| Potassium Chloride | 45 | $1,276 |
| Levetiracetam | 14 | $951 |
| Bumetanide | 16 | $904 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $24,108 | $1,281,17474 claims |
| NovartisEntresto | $241 | $147,33192 claims |
| AstraZenecaFarxiga | $338 | $81,46360 claims |
| Boehringer IngelheimJardiance | $31,133 | $56,30659 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.
Other advanced heart failure and transplant cardiology in Chicago
- Jonathan RichChicago$327K
- Esther VorovichChicago$224K
- Jane WilcoxChicago$220K
- Manreet KanwarChicago$162K
- Jonathan GrinsteinChicago$128K
- Quentin YoumansChicago$75K
- Anjan TibrewalaChicago$58K
- Faraz AhmadChicago$36K
- Ike OkwuosaChicago$30K
- Leo GozdeckiChicago$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.